| 2026-08-28 | Press release | New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients |
| 2026-08-28 | Press release | New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients |
| 2026-08-24 | Press release | New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026 |
| 2026-08-24 | Press release | New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026 |
| 2026-07-29 | Press release | Press release · Q2 2026 · Jul 2026 |
| 2026-07-29 | Press release | Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commer |
| 2026-07-29 | Press release | Press release · Q2 2026 · Jul 2026 |
| 2026-07-29 | Press release | Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence |
| 2026-07-29 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-29 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-28 | Deck | Amarin Corporate Overview Presentation |
| 2026-07-15 | Press release | Press release · Q2 2026 · Jul 2026 |
| 2026-07-15 | Press release | Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on |
| 2026-07-15 | Press release | Press release · Q2 2026 · Jul 2026 |
| 2026-06-30 | Press release | Press release · Jun 2026 |
| 2026-06-30 | Press release | Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatm |
| 2026-05-27 | Press release | Press release · May 2026 |
| 2026-05-27 | Press release | Press release · May 2026 |
| 2026-05-27 | Press release | New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted Apo |
| 2026-05-15 | 8-K | Form 8-K, Item 5.07 |
| 2026-04-29 | Press release | Amarin Reports 2026 First Quarter Financial Results |
| 2026-04-29 | Deck | Amarin Corporate Overview · Q1 2026 |
| 2026-04-29 | Press release | Press release · Q1 2026 · Apr 2026 |
| 2026-04-29 | Press release | Amarin Reports 2026 First Quarter Financial Results |
| 2026-04-29 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-29 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-15 | Press release | Press release · Q1 2026 · Apr 2026 |
| 2026-04-15 | Press release | Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on |
| 2026-04-15 | Press release | Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29 |
| 2026-04-10 | Proxy | Definitive proxy statement |
| 2026-04-08 | Press release | Press release · Apr 2026 |
| 2026-04-08 | Press release | American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including |
| 2026-04-08 | Press release | Press release · Apr 2026 |
| 2026-03-27 | 8-K | Form 8-K, Item 5.02 |
| 2026-03-18 | Press release | Press release · Mar 2026 |
| 2026-03-18 | Press release | Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Upd |
| 2026-03-18 | Press release | Press release · Mar 2026 |
| 2026-03-16 | Press release | Press release · Mar 2026 |
| 2026-03-16 | Press release | New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosa |
| 2026-03-16 | Press release | Press release · Mar 2026 |